Details of the Drug Reposition

General Information of This Drug (ID: DMZ2LGD)

Drug Name
Pramoxine   DMZ2LGD
Synonyms
Pramoxine hydrochloride; 637-58-1; Pramoxine HCl; Pramocaine hydrochloride; Prax Lotion; Tronolane; Tronothane hydrochloride; ProctoFoam-NS; Pramocaine (hydrochloride); UNII-88AYB867L5; HSDB 7220; EINECS 211-293-1; NSC 25573; Pramoxine hydrochloride [USP]; MLS000028604; Morpholine, 4-[3-(4-butoxyphenoxy)propyl]-, hydrochloride; 88AYB867L5; 4-(3-(p-Butoxyphenoxy)propyl)morpholine hydrochloride; p-Butoxyphenyl gamma-morpholinopropyl ether hydrochloride; gamma-Morpholinopropyl 4-n-butoxyphenyl ether hydrochloride; SMR000058670
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
6 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Exanthem DISAFOQN N.A. Approved [1]
Allergic otitis media DIS97RHR N.A. Approved [1]
Tinea cruris DIS5JC14 1F28.3 Approved [1]
Proctitis DIS3K8ZM DB33.Z Approved [1]
Anal fistula DISDQQDH DB50.1 Approved [2]
Burns DISA0PR2 N.A. Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)
3 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Otitis externa DISYCORK AA00-AA13 Discontinued in Phase 3 [3]
Hemorrhoids DISQ5G6G DB60 Discontinued in Phase 3 [4]
Dermatitis DISY5SZC EA80-EA89 Discontinued in Phase 3 [5]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Paroxysmal extreme pain disorder DISNHO6B N.A. Discontinued in Phase 2 [6]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pruritus DISVH62W EC90 Investigative [1]
------------------------------------------------------------------------------------

References

1 Pramoxine FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm
4 S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
5 Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis
6 Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma